Patterns of red blood cell utilization: Harnessing electronic health records data from the Information Standard for Blood and Transplant (ISBT) 128 system within the Biologics Effectiveness and Safety (BEST) initiative.

RBC transfusion hematology red cells

Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
30 Apr 2024
Historique:
revised: 09 04 2024
received: 09 08 2023
accepted: 10 04 2024
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 1 5 2024
Statut: aheadofprint

Résumé

Current hemovigilance methods generally rely on survey data or administrative claims data utilizing billing and revenue codes, each of which has limitations. We used electronic health records (EHR) linked to blood bank data to comprehensively characterize red blood cell (RBC) utilization patterns and trends in three healthcare systems participating in the U.S. Food and Drug Administration Center for Biologics Evaluation and Research Biologics Effectiveness and Safety (BEST) initiative. We used Information Standard for Blood and Transplant (ISBT) 128 codes linked to EHR from three healthcare systems data sources to identify and quantify RBC-transfused individuals, RBC transfusion episodes, transfused RBC units, and processing methods per year during 2012-2018. There were 577,822 RBC units transfused among 112,705 patients comprising 345,373 transfusion episodes between 2012 and 2018. Utilization in terms of RBC units and patients increased slightly in one and decreased slightly in the other two healthcare facilities. About 90% of RBC-transfused patients had 1 (~46%) or 2-5 (~42%)transfusion episodes in 2018. Among the small proportion of patients with ≥12 transfusion episodes per year, approximately 60% of episodes included only one RBC unit. All facilities used leukocyte-reduced RBCs during the study period whereas irradiated RBC utilization patterns differed across facilities. ISBT 128 codes and EHRs were used to observe patterns of RBC transfusion and modification methods at the unit level and patient level in three healthcare systems participating in the BEST initiative. This study shows that the ISBT 128 coding system in an EHR environment provides a feasible source for hemovigilance activities.

Sections du résumé

BACKGROUND BACKGROUND
Current hemovigilance methods generally rely on survey data or administrative claims data utilizing billing and revenue codes, each of which has limitations. We used electronic health records (EHR) linked to blood bank data to comprehensively characterize red blood cell (RBC) utilization patterns and trends in three healthcare systems participating in the U.S. Food and Drug Administration Center for Biologics Evaluation and Research Biologics Effectiveness and Safety (BEST) initiative.
METHODS METHODS
We used Information Standard for Blood and Transplant (ISBT) 128 codes linked to EHR from three healthcare systems data sources to identify and quantify RBC-transfused individuals, RBC transfusion episodes, transfused RBC units, and processing methods per year during 2012-2018.
RESULTS RESULTS
There were 577,822 RBC units transfused among 112,705 patients comprising 345,373 transfusion episodes between 2012 and 2018. Utilization in terms of RBC units and patients increased slightly in one and decreased slightly in the other two healthcare facilities. About 90% of RBC-transfused patients had 1 (~46%) or 2-5 (~42%)transfusion episodes in 2018. Among the small proportion of patients with ≥12 transfusion episodes per year, approximately 60% of episodes included only one RBC unit. All facilities used leukocyte-reduced RBCs during the study period whereas irradiated RBC utilization patterns differed across facilities.
DISCUSSION CONCLUSIONS
ISBT 128 codes and EHRs were used to observe patterns of RBC transfusion and modification methods at the unit level and patient level in three healthcare systems participating in the BEST initiative. This study shows that the ISBT 128 coding system in an EHR environment provides a feasible source for hemovigilance activities.

Identifiants

pubmed: 38689458
doi: 10.1111/trf.17852
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : U.S. Food and Drug Administration

Informations de copyright

© 2024 AABB.

Références

Goel R, Chappidi MR, Patel EU, Ness PM, Cushing MM, Frank SM, et al. Trends in red blood cell, plasma, and platelet transfusions in the United States, 1993‐2014. JAMA. 2018;319:825–827.
NHLBI. Blood transfusion [Monograph on the Internet]. 2020 Available from: https://www.nhlbi.nih.gov/health-topics/blood-transfusion
American Red Cross. Blood needs and blood supply [Monograph on the Internet]. 2020 Available from: https://www.redcrossblood.org/donate‐blood/how‐to‐donate/how‐blood‐donations‐help/blood‐needs‐blood‐supply.html
Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Clinical Transfusion medicine Committee of the a. red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med. 2012;157:49–58.
Simancas‐Racines D, Montero‐Oleas N, Vernooij RWM, Arevalo‐Rodriguez I, Fuentes P, Gich I, et al. Quality of clinical practice guidelines about red blood cell transfusion. J Evid Based Med. 2019;12:113–124.
Pavenski K, Stanworth S, Fung M, Wood EM, Pink J, Murphy MF, et al. Quality of evidence‐based guidelines for transfusion of red blood cells and plasma: a systematic review. Transfus Med Rev. 2018;32:135–143.
Shih AW, Liu A, Elsharawi R, Crowther MA, Cook RJ, Heddle NM. Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion. 2018;58:2841–2860.
AABB. Blood survey fact sheet [Monograph on the Internet]. 2016 Available from: http://www.aabb.org/research/hemovigilance/bloodsurvey/Pages/default.aspx
Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316:2025–2035.
Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. Transfusion. 2016;56:2173–2183.
Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, et al. Continued decline in blood collection and transfusion in the United States—2015. Transfusion. 2017;57(suppl 2):1588–1598.
Jones JM, Sapiano MR, Mowla S, Bota D, Berger JJ, Basavaraju SV. Has the trend of declining blood transfusions in the United States ended? Findings of the 2019 National Blood Collection and Utilization Survey. Transfusion. 2021;61:S1–S10.
Chada K, Obidi J, Gruber J, Storch E, Williams A, Banda J, et al. Transfusion trends of whole blood and blood components in electronic health records and claims databases. AABB Annual Meeting. Boston, MA. 2018.
Bassuni WY, Blajchman MA, Al‐Moshary MA. Why implement universal leukoreduction? Hematol Oncol Stem Cell Ther. 2008;1:106–123.
Birch RJ, Umbel K, Karafin MS, Goel R, Mathew S, Pace W. How do we build a comprehensive vein‐to‐vein (V2V) database for conduct of observational studies in transfusion medicine? Demonstrated with the recipient epidemiology and donor evaluation study‐IV‐pediatric V2V database protocol. Transfusion. 2023;63:1623–1632.

Auteurs

Joyce Obidi (J)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Gayathri Sridhar (G)

IQVIA Inc, Falls Church, Virginia, USA.

Graça M Dores (GM)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Barbee Whitaker (B)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Carlos H Villa (CH)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Emily Storch (E)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Kinnera Chada (K)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Lisa M Schilling (LM)

Data Science to Patient Value Program and Adult and Child Consortium for Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Karthik Natarajan (K)

Columbia University Medical Center, New York, New York, USA.

Paul Biondich (P)

Regenstrief Institute, Indianapolis, Indiana, USA.

Andrey Soares (A)

Data Science to Patient Value Program and Adult and Child Consortium for Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Matthew Spotnitz (M)

Columbia University Medical Center, New York, New York, USA.

Thomas Falconer (T)

Columbia University Medical Center, New York, New York, USA.

Saptarshi Purkayastha (S)

Regenstrief Institute, Indianapolis, Indiana, USA.

Nicole L Draper (NL)

Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Hui-Lee Wong (HL)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Matthew Stagg (M)

IQVIA Inc, Falls Church, Virginia, USA.

Christian Reich (C)

IQVIA Inc, Falls Church, Virginia, USA.

Steven Anderson (S)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Azadeh Shoaibi (A)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Classifications MeSH